FINAL Abstract Submission EXTENDED until April 30!

Directions on how to format your abstract submission
can be found at the bottom of this page

The Program Committee requests abstracts of your research for presentation at the 2025 In Vitro Biology Meeting. Abstracts will be accepted in electronic format only. SIVB’s online electronic abstract system includes submission, online payment, and confirmation capabilities.

The Final Abstract Submission Deadline to submit an abstract and guarantee placement in the program has been extended through April 30, 2025. 

Other Abstract information

Lightning Talks – Sparking Curiosity

Beginning in 2024, SIVB began offering a new presentation category: Lightning Talks. These concise 5-minute oral presentations are an opportunity for poster presenters to give a preview of their research and entice the audience to visit them in the Exhibit Hall. These special oral presentations will be limited to a maximum of 3 slides which will be advanced by a convener. Speakers are encouraged to keep their message simple, explain the broader significance or “big picture” of their research, and focus on key takeaways. Presenters will be able to provide greater details while standing at their poster during their assigned poster session immediately following the Lightning Talks. These presentations have replaced the Interactive Poster Sessions. We hope this combination Oral and Poster Presentation opportunity will be beneficial to both presenter and audience alike.

ROLLING ABSTRACT ACCEPTANCE AND MODIFICATION AFTER ACCEPTANCE

SIVB will be publishing all accepted abstracts after the meeting as a proceedings. This means that not only are abstracts being accepted and placed in the program after each deadline (March 31), but you now have an opportunity to modify your abstract after acceptance and provide the most accurate data in our final publication. Submit your abstract now to have guaranteed placement and the best chance to receive the presentation type you want in the program. Early placement will also allow you to apply for funding or visas. Should you receive updated results of your research, you can adjust your abstract up until the meeting. PLEASE NOTE: Significant modifications to your abstract may result in re-review of your submission by the Program Committee.

VIRTUAL POSTER PRESENTATIONS

Those who are unable to travel to the meeting in Norfolk, but are registering for On-Demand Limited Access can submit an abstract for consideration as a Virtual Poster Presentation. Virtual Poster authors will upload a pdf of their poster and will have the opportunity to record a description of their work.  You may choose the option for a “Virtual Poster” when you complete your submission. PLEASE NOTE: Please do not submit an abstract for a poster, lightning talk, or oral presentation if you are not attending the in-person meeting.

Silent Abstracts

The Silent Abstract is a special abstract category for authors unable to attend the meeting. Abstracts submitted for the Silent Abstract category follow the same abstract format, abstract fee, and scientific review/acceptance by the program committee; and, if accepted, will be printed in the abstract book. PLEASE NOTE: Please do not submit an abstract for a poster, lightning talk, or oral presentation if you are not attending the in-person meeting.

Student Abstract Verification Requirement

All abstracts submitted by students will be required to have their supervisor review and approve the submitted abstract in our online system. Students will need to include the name and email address of their professor/supervisor on the Author page when submitting their work. To complete the submission, the student’s supervisor will be sent a an email with a direct link to log into the Scorecard and approve the content and co-authors of the abstract. Once approved, the student will be allowed to log back in, then complete submitting the abstract. Directions for this process will also be provided when submitting your student abstract online.

Directions for Formatting Your Abstract

For instructions on how to format your abstract heading and abstract, and to view a sample of a properly formatted abstract to assist in you preparing your submission, CLICK HERE.

Sample Abstract

Assessing the Apoptosis Effect of Prenylated Stilbenoids Combined with Paclitaxel in Triple-negative Breast Cancer Cells. S. MOHAMMADHOSSEINPOUR^1,2, A. Weaver¹, L.-C. Ho¹, and F. Medina-Bolivar^1,3. ¹Molecular Biosciences Graduate Program, College of Sciences and Mathematics, Arkansas State University, Jonesboro, AR 72467; ²Arkansas Biosciences Institute, Arkansas State University, Jonesboro, AR 72467; and ³Department of Biological Sciences, Arkansas State University, Jonesboro, AR 72467. Email: [email protected]

Breast cancer is one of the most prevalent types of cancer in women worldwide. Triple-negative breast cancer (TNBC) is unresponsive to typical hormonal treatments causing it to be one of the deadliest forms of breast cancer. Investigating alternative therapies to increase survival rates for this disease is essential. This study aimed to examine if prenylated stilbenoids from peanut can act as an adjuvant for paclitaxel, a chemotherapeutic drug with severe side effects. The prenylated stilbenoids arachidin-1 (A-1) and arachidin-3 (A-3) are analogs of resveratrol (RES) and were produced in hairy root cultures of peanut. The cytotoxicity activity of A-1, A-3, and RES was studied in TNBC cell lines MDA-MB-231 and MDA-MB-436. Furthermore, the cytotoxicity of A-1, the most potent prenylated stilbenoid, combined with paclitaxel was studied by checkerboard assays in the TNBC cell lines. The apoptotic effects of this combination treatment were studied by western blotting targeting protein expression levels of PARP, caspase-8, caspase-9, and survivin and through the Apo-ONE Homogeneous Caspase-3/7 assay. To further investigate the apoptosis and cell cycle stages, cells treated with prenylated stilbenoids or RES were studied using flow cytometry. After 24 hours of treatment, A-1 exhibited higher cytotoxicity than A-3 and RES with approximately 11-fold and 6-fold lower IC50, respectively, in MDA-MB-231 cells, and 9-fold and 8-fold lower IC50, respectively, in MDA-MB-436 cells. A-1 did not show significant cytotoxicity in the non-cancerous cell line MCF-10A. Cytotoxicity, checkerboard, and flow cytometry assays showed a decrease in paclitaxel concentration when combined with prenylated stilbenoids. This highlights the significance of continuing research with prenylated stilbenoids as an adjuvant in TNBC treatment.